



## Alaska Medicaid Policy Clarification Pharmacogenetics Testing

### Policy

Pharmacogenetics testing panels (e.g., GeneSight Psychotropic, Genecept Assay, SureGene Test, and Mental Health DNA Insight Panel), are **not covered** by Alaska Medicaid for any indication, including psychotropic or pain medication prescribing.

Codes for individual components of pharmacogenetics test panels are **not covered** for any indication including treatment with any psychotropic or pain medications, with the exception of the following medically necessary situations:

- CPT 81225 (CYP2C19) is **covered only** for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) who are initiating or reinitiating Clopidogril (Plavix); 81225 is not covered for patients on psychotropic or pain medications.
- CPT 81226 (CYP2D6) is **covered only** if one or more of the following criteria are met:
  - ✓ Patient is on doses of Pimozide of more than 4mg/day (adult) or 0.05mg/day (child);
  - ✓ Patient with Gaucher disease type 1 and is a candidate for and is considering treatment with eliglustat, and who have received medication prior authorization approval under the pharmacy benefit;
  - ✓ Patient who has failed at least two other antidepressants being initiated on antidepressant therapy with amitriptyline or nortriptyline. CPT 81226 (CYP2D6) will not be authorized for a patient prescribed amitriptyline or nortriptyline for neuropathic pain indicationsCPT 81226 is **not covered** for patients on tetrabenazine, as the cost of the sample kit and test are covered by Lundbeck for patients with a Xenazine Treatment Form\* on file.
- CPT 81227 (CYP2C9) is **not a covered service**.

### Documentation Requirements

Claims for **all** genetic testing must be accompanied by a [Genetic Testing Supporting Information](#) form and a lab report. Failure to attach these documents will result in claim denial.

### Background

Evidence regarding the effectiveness of genetic testing for patients taking psychotropic or pain medicine to guide their pharmaceutical treatment is limited or non-existent. Pharmacogenetics testing, including multigene panels, is almost always experimental and investigational for patients taking psychotropic or pain medicines and is only rarely medically necessary. Alaska Medicaid will not pay for an experimental or investigational service, including one where insufficient data exists for its use (7 AAC 105.110(7)(B)).

\* CYP2D6 Support Program, Xenazine® (tetrabenazine). <https://www.xenazineusa.com/HCP/TreatmentExpectations/CYP2D6SupportProgram>